Oral therapy for erectile dysfunction: An overview
Main Article Content
the development of less-invasive modalities. Oral drugs have become the first-line therapeutic option for many men with ED. This review highlights the pathophysiology of ED, oral therapy for ED and new drug targets for the treatment of ED
products available in the market for ED.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
NIH Consensus Conference. Impotence NIH Consensus Development
Panel on Impotence. JAMA 1993;270:83-90.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB.
Impotence and its medical and psychosocial correlates: Results of the
Massachusetts Male Aging Study. J Urol 1994;151:54-61.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States:
Prevalence and predictors. JAMA 1999;281:537-44.
Aytac IA, McKinley JB, Krane RJ. The likely worldwide increase in
erectile dysfunction between 1995 and 2025 and some possible policy
consequences. BJU Int 1999;84:50-6.
de Tejada SI, Blanco R, Goldstein I, Azadzoi K, De Las Morenas A,
Krane RJ, et al. Cholinergic neurotransmission in human corpus
cavernosum. I. Responses of isolated tissue. Am J Physiol 1988;25:459-67.
Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric
oxide and cyclic GMP formation upon electrical field stimulation cause
relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res
Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: New
insights and more questions. J Urol 1993;149:1246-55.
Melman A, Gingell JC. The epidemiology and pathophysiology of erectile
dysfunction. J Urol 1999;161:5-11.
Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The
relationship between depressive symptoms and male erectile
dysfunction: Cross-sectional results from the Massachusetts Male Aging
Study. Psychosom Med 1998;60:458-65.
Cooke JP. Therapeutic interventions in endothelial dysfunction:
endothelium as a target organ. Clin Cardiol 1997;2:45-51.
Pfizer Inc. Viagra (sildenafil citrate) tablets: Prescribing information.
Pfizer Inc; 2000.
Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro
and on the activities of cyclic nucleotide phosphodiesterase isozymes.
J Urol 1998;159:2164-71.
Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen Rc.
Sildenafil citrate (Viagra) in erectile dysfunction: Near normalization
in men with broad-spectrum erectile dysfunction compared with
age- atched healthy control subjects. J Urol 1999;53:800-5.
mRendell MS, Rajfer J, Wicker PA, Smith MD for the Sildenafil Diabetes
Study Group. Sildenafil for treatment of erectile dysfunction in men
with diabetes: A randomized controlled trial JAMA 1999;281:421-6.
Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update
of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract
Olsson AM, Persson CA. Efficacy and safety of sildenafil citrate for the
treatment of erectile dysfunction in men with cardiovascular disease.
Int J Clin Pract 2001;55:171-6.
Zesiewicz TA, Hauser RA, Helal M. Sildenafil citrate (Viagra) for the
treatment of erectile dysfunction in men with Parkinsonâ€™s disease.
Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with
spina bifida is a treatable condition. J Urol 2000;164:958-61.
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety
of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
Int J Impot Res 1998;10:69-74.
Heaton JP. Key issues from the clinical trials of apomorphine SL. World
J Urol 2001;19:25-31.
Mulhall JP, Bukofzer S, Edmonds AL, George M; Apomorphine SL
Study Group. An open-label, uncontrolled dose-optimization
study of sublingual apomorphine in erectile dysfunction. Clin Ther
Morales A. Yohimbine in erectile dysfunction: The facts. Int J Impot Res
Porst H. IC351 (tadalafil, Cialis): Update on clinical experience. Int
J Impot Res 2002;14:57-64.
Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E,
et al. The efficacy and tolerability of vardenafil, a new, oral, selective
phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction:
The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: A novel player in the
regulation of penile erection. Int J Impot Res 2001;13:67-72.
Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP,
Morgan RJ. Alterations in endothelin B receptor sites in cavernosal
tissue of diabetic rabbits: Potential relevance to the pathogenesis of
erectile dysfunction. J Urol 1997;158:1966-72.
Available from: http://www.natural-cure-guide.com
Available from: www.altmedicine zone.com